STOCK TITAN

Novamind to Present at LD Micro and KCSA Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Novamind Inc. (CSE:NM, OTCQB:NVMDF) announced participation in two virtual investor conferences on October 13, 2021. CEO Yaron Conforti will discuss the Company's efforts to enhance access to psychedelic medicine, including the opening of its sixth clinic and a new Psychedelic Palliative Care program. The conferences include the LD Micro Main Event XIV at 10:30 AM EST and the KCSA Psychedelics Virtual Investor Conference at 1:00 PM EST. For more information, visit novamind.ca.

Positive
  • None.
Negative
  • None.

TORONTO, ON / ACCESSWIRE / October 8, 2021 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, today announced participation in two upcoming virtual investor conferences on Wednesday, October 13, 2021.

Novamind's CEO and Director, Yaron Conforti, will present the Company's progress towards expanding access to psychedelic medicine in the U.S., including the recent opening of the Company's sixth clinic and the newly launched Psychedelic Palliative Care program.

Virtual LD Micro Main Event XIV
Date: October 13, 2021
Time: 10:30 AM to 11:00 AM EST
Register and watch live here: me21.mysequire.com

KCSA Psychedelics Virtual Investor Conference
Date: October 13, 2021
Time: 1:00 PM to 1:30 PM EST
Register and watch live here: www.virtualinvestorconferences.com/events/event-details/psychedelics-virtual-investor-conference

About Novamind
Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics and clinical research sites. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of Cedar Psychiatry clinics and operates Cedar Clinical Research, a contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. Both Cedar Psychiatry and Cedar Clinical Research are wholly owned subsidiaries of Novamind. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visitnovamind.ca.

Contact Information
Novamind
Yaron Conforti, CEO and Director
Telephone: +1 (647) 953-9512

Samantha DeLenardo, VP, Communications
Email: media@novamind.ca

Bill Mitoulas, Investor Relations
Email: bill@novamind.ca

Forward-Looking Statements

This news release contains forward-looking statements. All statements other than statements of historical fact included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations including the risks detailed from time to time in the Company's public disclosure. The reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable laws.

SOURCE: Novamind Inc.



View source version on accesswire.com:
https://www.accesswire.com/667315/Novamind-to-Present-at-LD-Micro-and-KCSA-Conferences

FAQ

What are the details of Novamind's participation in the October 2021 investor conferences?

Novamind Inc. will participate in two virtual conferences on October 13, 2021. The LD Micro Main Event XIV is scheduled for 10:30 AM to 11:00 AM EST, and the KCSA Psychedelics Virtual Investor Conference will occur from 1:00 PM to 1:30 PM EST.

Who is representing Novamind at the investor conferences?

Yaron Conforti, the CEO and Director of Novamind, will present at both conferences.

What new programs is Novamind launching?

Novamind has launched a new Psychedelic Palliative Care program aimed at enhancing access to psychedelic medicine.

What is the significance of Novamind's sixth clinic opening?

The opening of Novamind's sixth clinic marks a significant step in expanding access to psychedelic medicine in the U.S.

Where can I find more information about Novamind's investor conferences?

More information about Novamind's participation in the investor conferences can be found on their official website, novamind.ca.

NVMDF

:NVMDF

NVMDF Rankings

NVMDF Latest News

NVMDF Stock Data

12.97M
37.62M
31.68%
0%
Medical Care Facilities
Healthcare
Link
Canada
Toronto